Carbapenem resistance in gram-negative bacilli isolates in an iranian 1000-bed tertiary hospital

Pakistan Journal of Medical Sciences

Volumn 24, Issue 4, 2008, Pages 537-540

  Rahbar, Mohammad ^a   Kabeh Monnavar, Mohammad ^b   Vatan, Kamal Khadem ^c   Fadaei haqi, Asgar ^d   Shakerian, Farshad ^d  

^a Iranian Reference Health Laboratory   (Iran)

^b MILAD HOSPITAL   (Iran)

^c URMIA UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Carbapenem resistance; Non fermenter gram negative bacilli

Indexed keywords

AMIKACIN; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL STRAIN; DISEASE PREDISPOSITION; DISK DIFFUSION; GRAM NEGATIVE BACTERIUM; HOSPITAL BED CAPACITY; HOSPITAL PATIENT; HUMAN; IRAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; PSEUDOMONAS AERUGINOSA; TERTIARY HEALTH CARE;

EID: 51849085345     PISSN: 1682024X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Gladstone P, Rajendran P, Brahmthan KN. Incidence of carbapenem resistant nonfermenting gram -negative bacilli from patients with respiratory infections in the intensive care units. Indi J Med Microbiol 2005;23:189-91.
2. Rodloff AC, Goldstein EJ, Torres A. Two decades of imipenem therapy. J Antimicrob Chemother 2006;58:916-29.
3. Matsumoto T, Kumazawa J, Nagayama. A sensitivities to four carbapenems of bacteria isolated from patients with refractory complicated urinary tract infections and the detection of carbapenemase-producing Pseudomonas aeruginosa. J Antimicrob Chemothe1996;38:322-4.
4. Zhanel GG, Wiebe R, Dilay L, Thomson K, Rubinstein E, Hoban DJ, et al. Comparative review of the carbapenes. Drug 2007;67:1027-52.
5. Spencer BA, Richard III JW, McCoy LF, Carino E, Washington J, Edgar P, et al. Antibiotic activity of meropenem on Multi-resistant gram-negative organisms. J Burns Surg 2002;1:12-17.
6. Hellinger W, Brewe N. Carbapenems & monobactame: meropenem & aztreonam. Mayo Clinic Proc 1999;74:420-34.
7. Gales AC, Jones RN, Turnidge J, Ramphal R. Characterization of Pseudomonas aeruginosa isolates occurrence rates, antimicrobial susceptibility patterns and molecular typing in the global antimicrobial surveillance program 1997-1999. Clin Infect Dis 2001;32:S146-55.
8. National Committee for clinical Laboratory Standards (NCCLS). Performance standards for antimicrobial disk susceptibility tests 8th ed. Approved standards. NCCLS Document M2-A8, Wayne PA. 2003.
9. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing; 16th informational supplement M100- S 16 CLSI, Wayne. PA 2006.
10. Gupta E, Mohanty S, Sood S. Emerging resistance to carbapenems in a tertiary care hospital in north India. India J Med Res 2006;124:95-8.
11. Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006;12:826-36.
12. Manuel RJ, Shin GY, Farraq N, Holliman R. Endemic carbapenem -resistant Acintobacter baumannii in a London hospital. J Antmicrobiol Chemother 2003;52:141-2.
13. Feizabadi MMC. Etemadi D, Yadegari D. Antibiotic -resistance patterns and frequency of extended -spectrum β-lactamase -producing isolates of Klebsiella pneumoniae in Tehran. Med Sci Monit 2006;12:362-5.
14. Ahangarzadeh-Rezaee M, Behzadian Nejad Q, Owlia P, Pirrayeh S- najjar. In-vitro-activity of imipenem and ceftazidime against mucoid and non-mucoid strains of Pseudomonas aeruoginsa isolated from patients in Iran. Arch Iranin Med 2002;5:108-10.
15. Moniri R, Mosayebi AH, Movahedian GH. A Mossavi Increasing of antimicrobial drug-resistance in Pseudomonas aeruginosa causing septicemia. Iranian J Publ Health 2006;32:58-62.